WO2002095053A3 - Antisense modulation of src-c expression - Google Patents

Antisense modulation of src-c expression Download PDF

Info

Publication number
WO2002095053A3
WO2002095053A3 PCT/US2002/015684 US0215684W WO02095053A3 WO 2002095053 A3 WO2002095053 A3 WO 2002095053A3 US 0215684 W US0215684 W US 0215684W WO 02095053 A3 WO02095053 A3 WO 02095053A3
Authority
WO
WIPO (PCT)
Prior art keywords
src
expression
antisense modulation
methods
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/015684
Other languages
French (fr)
Other versions
WO2002095053A2 (en
Inventor
Frank C Bennett
Andrew T Watt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Priority to AU2002318139A priority Critical patent/AU2002318139A1/en
Priority to US10/476,962 priority patent/US20040191904A1/en
Priority to EP02747842A priority patent/EP1404699A2/en
Publication of WO2002095053A2 publication Critical patent/WO2002095053A2/en
Publication of WO2002095053A3 publication Critical patent/WO2002095053A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Antisense compounds, compositions and methods are provided for modulating the expression of src-c. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding src-c. Methods of using these compounds for modulation of src-c expression and for treatment of diseases associated with expression of src-c are provided.
PCT/US2002/015684 2001-05-18 2002-05-16 Antisense modulation of src-c expression Ceased WO2002095053A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2002318139A AU2002318139A1 (en) 2001-05-18 2002-05-16 Antisense modulation of src-c expression
US10/476,962 US20040191904A1 (en) 2001-05-18 2002-05-16 Antisense modulation of src-c expression
EP02747842A EP1404699A2 (en) 2001-05-18 2002-05-16 Antisense modulation of src-c expression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/860,473 2001-05-18
US09/860,473 US6656732B1 (en) 2001-05-18 2001-05-18 Antisense inhibition of src-c expression

Publications (2)

Publication Number Publication Date
WO2002095053A2 WO2002095053A2 (en) 2002-11-28
WO2002095053A3 true WO2002095053A3 (en) 2003-05-01

Family

ID=25333295

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/015684 Ceased WO2002095053A2 (en) 2001-05-18 2002-05-16 Antisense modulation of src-c expression

Country Status (4)

Country Link
US (2) US6656732B1 (en)
EP (1) EP1404699A2 (en)
AU (1) AU2002318139A1 (en)
WO (1) WO2002095053A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040005707A1 (en) * 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of integrin beta 5 expression
US20030096772A1 (en) * 2001-07-30 2003-05-22 Crooke Rosanne M. Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US20030232778A1 (en) * 2002-06-17 2003-12-18 Marcusson Eric G. Extracellular-signal-regulated kinase-6 inhibitors for inhibiting angiogenesis
US20030232772A1 (en) * 2002-06-17 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of extracellular-signal-regulated kinase-6 expression
US20060003953A1 (en) * 2003-12-04 2006-01-05 Bennett C F Compositions and their uses directed to bone growth modulators
DE102004013842A1 (en) 2004-03-20 2005-10-13 Degussa Ag Nitrile hydratases from metagenome libraries
ATE498685T1 (en) 2004-06-28 2011-03-15 Univ Western Australia ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHOD FOR THE USE THEREOF
USRE48960E1 (en) 2004-06-28 2022-03-08 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US20060287273A1 (en) * 2005-06-16 2006-12-21 Fujita Donald J Methods and reagents for inhibiting cell proliferation
CN112574988A (en) 2008-10-24 2021-03-30 萨雷普塔治疗公司 Multi-exon skipping compositions for DMD
LT2499249T (en) 2009-11-12 2018-12-27 The University Of Western Australia Antisense molecules and methods for treating pathologies
NZ731587A (en) 2013-03-14 2021-07-30 Sarepta Therapeutics Inc Exon skipping compositions for treating muscular dystrophy
CA2906812A1 (en) 2013-03-15 2014-09-18 Sarepta Therapeutics, Inc. Improved compositions for treating muscular dystrophy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5734039A (en) * 1994-09-15 1998-03-31 Thomas Jefferson University Antisense oligonucleotides targeting cooperating oncogenes
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
WO1999013886A1 (en) 1997-09-17 1999-03-25 East Carolina University Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications
AU1536999A (en) 1997-11-26 1999-06-15 Board Of Regents, The University Of Texas System Modified sv40 viral vectors
WO1999047690A2 (en) 1998-03-16 1999-09-23 Introgen Therapeutics, Inc. Multigene vectors
ATE340560T1 (en) 1999-05-24 2006-10-15 Introgen Therapeutics Inc METHODS AND COMPOSITIONS FOR NONVIRAL GENE THERAPY FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
EP1194527A4 (en) 1999-06-28 2004-04-14 Univ Southern California Stress-responsive induction of a therapeutic agent and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5734039A (en) * 1994-09-15 1998-03-31 Thomas Jefferson University Antisense oligonucleotides targeting cooperating oncogenes

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRANCH A.D.: "A good antisense is hard to find", TIBS, vol. 23, February 1998 (1998-02-01), pages 45 - 50, XP000938938 *
CHELLAIAH ET AL.: "c-Scr is required for stimulation of gelsolin-associated phosphatidylinositol 3-kinase", THE JOURNAL OF BOLOGICAL CHEMISTRY, vol. 273, no. 19, 8 May 1998 (1998-05-08), pages 11908 - 11916, XP002956434 *
MARZIA ET AL.: "Decreased c-Scr expression enhances osteoblast differentation and bone formation", THE JOURNAL OF CELL BIOLOGY, vol. 151, no. 2, 16 October 2000 (2000-10-16), pages 311 - 320, XP002956437 *
NARUSE ET AL.: "Uni-axial cyclic stretch induces c-scr activation and translocation in human endothelial cells via SA channel activation", FEBS LETTERS, vol. 441, December 1998 (1998-12-01), pages 111 - 115, XP004258882 *
STALEY ET AL.: "Decreased turmorigenicity of a human colon adenocarcinoma cell line by an antisense expression vector specific for c-Src", CELL GROWTH AND DIFFERENTIATION, vol. 8, March 1997 (1997-03-01), pages 269 - 274, XP002956436 *
TANAKA ET AL.: "c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption", NATURE, vol. 383, 10 October 1996 (1996-10-10), pages 528 - 531, XP002956435 *

Also Published As

Publication number Publication date
WO2002095053A2 (en) 2002-11-28
EP1404699A2 (en) 2004-04-07
AU2002318139A1 (en) 2002-12-03
US6656732B1 (en) 2003-12-02
US20040191904A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
WO2002092772A3 (en) Antisense modulation of ptp1b expression
WO2003011887A3 (en) Antisense modulation of apolipoprotein b expression
WO2002036743A3 (en) Antisense modulation of calreticulin expression
WO2004044181A3 (en) Antisense modulation of apolipoprotein b expression
WO2003014307A3 (en) Antisense modulation of apolipoprotein(a) expression
WO2002010378A3 (en) Antisense modulation of ptp1b expression
WO2003097662A8 (en) Antisense modulation of apolipoprotein b expression
WO2003008543A3 (en) Antisense modulation of bcl2-associated x protein expression
WO2003010284A3 (en) Antisense modulation of c-reactive protein expression
WO2003066805A3 (en) Antisense modulation of complement component c3 expression
WO2003046132A3 (en) Antisense modulation of myd88 expression
WO2003022222A3 (en) Antisense modulation of protein kinase r expression
WO2003053341A3 (en) Antisense modulation of ship-1 expression
WO2003008545A3 (en) Antisense modulation of glioma-associated oncogene-2 expression
WO2002095053A3 (en) Antisense modulation of src-c expression
WO2002036810A3 (en) Antisense modulation of talin expression
WO2003052062A3 (en) Antisense modulation of cd36l1 expression
WO2003099224A3 (en) Antisense moodulation of kinesin-like 1 expression
WO2003027229A3 (en) Antisense modulation of rip2 expression
WO2003050247A3 (en) Antisense modulation of mhc class ii transactivator expression
WO2003040161A3 (en) Antisense modulation of activating transcription factor 3 expression
WO2003044167A3 (en) Antisense modulation of human fxr expression
WO2003031576A3 (en) Antisense modulation of inhibitor-kappa b kinase-gamma expression
WO2002041836A3 (en) Antisense modulation of src-1 expression
WO2004014299A3 (en) Antisense modulation of resistin expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10476962

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002747842

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002747842

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002747842

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP